In diabetic patients who were diagnosed with COVID-19, SGLT2 inhibitor treatment showed benefits for cardiovascular outcomes, but not for pneumonia or sepsis. The gene discussed is SLC5A2; the disease is susceptibility to pneumonia measurement.